Ucla Medical Device Partnering Conference

INDUSTRY

INVENTORS

INVESTORS 3RD ANNUAL UCLA MEDICAL DEVICE PARTNERING CONFERENCE

TUESDAY MARCH 10, 2015 CNSI UCLA CAMPUS

Conference Program

9:15 am REGISTRATION/NETWORKING

10:00 am WELCOME—Emily Waldron Loughran

11:30 am TRENDS IN HOSPITAL PURCHASING OF MEDICAL DEVICES UCLA Health | Kaiser Permanente

12:15 pm LUNCH

1:15 pm STARTUP COMPANY PITCHES Bone-Rad Therapeutics | Bruin Biometrics | Fluid Synchrony | QT Medical

2:15 pm NETWORKING OPPORTUNITIES

2:45 pm STARTUP COMPANY PITCHES CaliCast | Cayuga Biotech | GI Logic | Platinum Group Coatings

3:45 pm NETWORKING/EVENT CLOSE

Speaker Profiles 2

Startup Company Profiles 7

UCLA Available Medical Device Technologies 11

Cardiovascular Devices 12

CNS Technologies 14

Device Materials 15

Diagnostic Tools 16

Orthopedic Devices 19

Radiation Therapy & Oncology 19

Sensors & Patient Monitoring Devices 20

Surgical Tools 22

Conference Sponsors and Partner Organizations 25

Contact Information 26 Richard M. Brenner Andy DelGesso President & C.E.O. Executive Director and Medical Portfolio Manager The Brenner Group, Inc. Kaiser Permanente

Rich Brenner founded The Brenner Group, Andy DelGesso is an Executive Director and Medical Inc.® (www.thebrennergroup.com) in 1987. The Portfolio Manager in Procurement & Supply at Brenner Group is a financial services firm providing Kaiser Permanente. In addition to managing $1.5B outsourced financial executives, financial advisory in purchases of medical products, equipment services and shareholder representative services and and services, he is active in Business Strategy serves as CEO. Development, Digital Health Integration, Supplier Relationship Management, and Outsourced Services He has also been an active angel investor in and Management. around Silicon Valley for many years. Andy has 20 years of experience in Strategic Sourcing One of these investments is Bridge Capital Holdings, and Supply Chain functions, both in the U.S. and the parent company of Bridge Bank, where Rich is abroad. His background includes work in many a founder, Director Emeritus, former member of the industries, including healthcare, IT, automotive, Board of Directors and former Chairman of the Audit agriculture, & manufacturing. Committee. Recently, he has focused his Angel Investing in the life sciences sector. Andy holds a bachelor’s degree in Business from Villanova University and is fluent in Japanese. He has worked in general and financial management, and has assisted many emerging companies in the roles of President, General Manager, Vice President and Chief Financial Officer. He has held executive level positions at Formaster Corporation, Corvus Systems Inc., US Leasing International Inc., ITEL Corporation, National BankAmericard (now VISA) and Autographic Business Forms Inc. He also served as venture capital consultant to Hillman Ventures.

Rich is, or has served, as a board member at Affymax, Inc., e-Nicotine, Inc., Sandstone Diagnostics, Inc., PartMiner, Inc. Vida Systems, Inc., Vello Systems, Inc., Abound Logic, Inc., Pavad Medical Systems, Inc. Cardiovention, Inc., Chadmoore Wireless Group and QuickHealth.

2 UCLA Medical Device Partnering Conference Norm Gitis, PhD Paul M. Grand Managing Partner, Lymo Ventures Managing Director Screening Committee Chair, Life Science Angels RCT Ventures

Norm Gitis obtained his PhD in Engineering from Paul M. Grand is a Managing Director for RCT the USSR Academy of Sciences in Moscow. Upon Ventures. At RCT, he is responsible for sourcing immigration to the US, he was a visiting professor at RCT’s investments in medical devices and MIT until IBM moved him to San Jose. He worked in representing RCT on the boards of its portfolio the disk drive industry, at IBM and then Maxtor. companies. Grand serves as Producer and Master of Ceremonies for the annual MedTech Idol Norm founded and ran two high-tech companies, competition that seeks to identify outstanding early- Center for Tribology, Inc. in Mountain View (1994– stage MedTech opportunities. 2000) and CETR in Campbell (2000–2011). He was twice named by the Business Journal the CEO of Grand has extensive experience in new company Top 20 Fastest Growing Private Companies in formation and operations. Prior to joining RCT, Northern California. Grand founded and operated eight high technology, medical device, and biotechnology companies. In Norm has authored over 150 scientific papers, three the life sciences, Grand was co-founder and VP of books and over two dozen patents, chaired and Operations of Imagine Pharmaceuticals, and co- organized over three dozen international scientific founder and CEO of MicroSurgeon in Los Angeles. conferences. Grand is actively involved in programs to Over the past three years, Norm has been pursuing encourage bio-entrepreneurship, innovation, and his passion of helping technology-based start-ups commercialization of University technologies. He with funding, IP and business development. Norm is on the Oversight Committees for the Coulter chairs a screening committee of Life Science Angels Translational Research Partnership Programs at USC and serves on a screening committee of the Band and University of Washington. Grand is a reviewer of Angels. for proof of concept and commercialization-focused funding programs for the University of California system, USC, University of Utah, and University of Colorado.

UCLA Medical Device Partnering Conference 3 Thomas Lipkin, PhD Emily Waldron Loughran Head of New Ventures Director of Licensing UCLA OIP-ISR UCLA OIP-ISR

Thomas Lipkin joined UCLA’s OIP-ISR in 2012 Emily Loughran joined UCLA’s OIP-ISR in 1994 as a and serves as Head of New Ventures. Dr. Lipkin technology transfer officer. Currently, as the Director and his team work to further the entrepreneurial of Licensing, she manages the licensing and patent environment at UCLA by building startup companies prosecution groups, and oversees the office’s large around UCLA’s intellectual property, serving as a portfolio of invention disclosures, patents, and resource to faculty members, aiding existing UCLA license agreements. Emily started in intellectual startups in sourcing financing and talent, and property administration at the City of Hope Medical helping secure additional funding for campus-wide Center where she was the Technology Transfer startup initiatives. Dr. Lipkin is also responsible Manager responsible for patenting and licensing for actively promoting UCLA’s intellectual property activities. Emily holds an MBA from USC and a BS assets and engaging with parties interested in from UC Berkeley. further developing early-stage technologies in the life sciences, physical sciences, and internet technology space. Previously, Dr. Lipkin was with Osage University Partners, a venture capital fund that invests exclusively in university-based startup companies. Dr. Lipkin received his B.S. in Biology from Indiana University and his Ph.D. in Cell Biology and Pathology from Columbia University.

4 UCLA Medical Device Partnering Conference Jennifer McKeever, MSc, BSc Brian O’Neill, PhD, MBA Senior Investment Analyst Manager, High Potential Start-Ups, Industrial & Seroba Kernel Life Sciences Lifesciences, High Growth Scaling Unit Enterprise Ireland

Jennifer McKeever joined the team of Seroba Kernel Brian O’Neill is the Head of Industrial & Lifesciences in 2011. She graduated from University College, High Potential Start-Ups for Enterprise Ireland— Dublin with an honours degree in Pharmacology the Government of Ireland’s Trade and Technology in 2010. Jennifer then entered a Master’s degree Agency responsible for the internationalisation of programme in Biotechnology and Business to further indigenous Irish industry. Brian has spent over her interest in the interface of biomedical science with 20 years working with the lifesciences sector in commercialisation. Having placed first in her Master’s Ireland and internationally in a variety of private degree in 2011, Jennifer then joined Seroba Kernel’s sector/government roles ranging from basic Investment Team as an Investment Analyst. Jennifer is to applied research through to entrepreneur, a member of the Sandbox network, a global community technology transfer specialist, lifesciences business for ‘exceptional innovators’ and she guest-lectures on development adviser and Head of the indigenous venture capital at University College Dublin, Trinity Irish sector. College Dublin and the Royal College of Surgeons, In his current role Brian and his team are Ireland. Jennifer was promoted to Senior Analyst in responsible for the development and implementation 2014. of the strategic plan required to drive the continued Seroba Kernel is a European life sciences venture growth of Ireland’s vibrant start up community capital firm, focused on investing in breakthrough together with accelerating the global expansion of healthcare technologies that promise to improve lives Ireland’s most successful businesses. In addition, and make a difference worldwide. Headquartered he plays a key role in shaping the Irish ecosystem to in Ireland, we work with some of Europe’s best ensure its long-term development and evolution. entrepreneurs developing innovative medical devices, Brian had a PhD in Human Molecular Genetics diagnostics and therapeutic drugs. from Trinity College Dublin, Ireland and a 1st Class Honours Masters of Business Administration from University College Dublin, Ireland.

For further information on Enterprise Ireland, please see www.enterprise-ireland.com

UCLA Medical Device Partnering Conference 5 Jenell Paul, MSN, RN Renee Compton Ryan Clinical Procurement Specialist Vice President UCLA Health Venture Investments Johnson & Johnson Innovation—JJDC

Jenell Paul has been employed at UCLA Health for Renee Compton Ryan joined Johnson & Johnson 18 years. She has worked in both the inpatient and Innovation—JJDC, Inc. (JJDC) in 2011. She is based operational areas. Currently she is responsible for in Silicon Valley, California and primarily supports the value analysis initiatives, including new technology strategic investment activities in medical devices and assessments, contracting, evaluations, and product diagnostics. conversions, for the UCLA Health System. Jenell contributes to clinical quality of care by assessing Mrs. Ryan’s background includes over 20 years of introduced products for compliance with the UCLA healthcare investment banking. Most recently, she goal to deliver patient-focused, cost-effective, ran the medical device investment banking effort quality care. She is the Clinical Procurement at R.W. Baird & Co. Previously, she lead the West Specialist and Value Analysis Coordinator for the Coast medical device group at Jefferies & Co. and UCLA Health System. was in the healthcare investment banking groups at Goldman Sachs and Credit Suisse.

Mrs. Ryan received an MBA from Columbia Business School and a Bachelors degree from Georgetown University.

6 UCLA Medical Device Partnering Conference Startup Company Profiles

http://www.bone-rad.com/ http://bruinbiometrics.com/

Bone-Rad Therapeutics, has developed a proprietary Bruin Biometrics, LLC (BBI) was founded in 2009 Brachytherapy Bone Cement for the treatment on the insight that sensing technology could of bone tumors. Bone-Rad’s first product, Spine- be developed to detect and monitor diseases Rad™ Cement, will simplify the treatment paradigm earlier and with greater diagnostic certainty than for cancer tumors of the vertebrae. The current prevailing methods. BBI identifies, develops and treatment for vertebral tumors is a two-step process commercializes devices that use biometric sensors starting with vertebroplasty or kyphoplasty to to noninvasively measure bodily changes that strengthen the bone, followed by 10-20 visits for are indicative of the early stages and progression external beam radiation therapy (EBRT) to kill the of disease states. These biomarkers offer new, tumor. Spine-Rad Cement, which incorporates a immediate, inexpensive and clinically valuable radionuclide, is injected into the vertebral body medical data at the point of care. as part of a standard kyphoplasty procedure and delivers a therapeutic radiation dose to the tumor BBI’s lead product—the SEM Scanner™ — is while simultaneously strengthening the vertebral a revolutionary, sensor-based medical device body. Spine-Rad will eliminate the 10-20 hospital which received CE mark in Europe in 2013, for visits typically needed for EBRT, making the the detection of early stage Pressure Ulcers and treatment of vertebral tumors less expensive, while suspected Deep Tissue Injury. With up to 91% true dramatically reducing the unpleasant side effects positive and 86% of true negative performance, associated with EBRT and greatly improving patient The SEM Scanner™ Makes Pressure Ulcer care and quality of life. Prevention Possible.

UCLA Medical Device Partnering Conference 7 Startup Company Profiles

Cayuga Biotech

http://www.cayugabiotech.com/

Traditional casts are bulky, smelly, uncomfortable, Trauma and hemorrhage are intertwined conditions subject to molding and degradable in water. CaliCast that account for the number one cause of death and is a next generation cast and turn-key casting system disability worldwide. In the US, blood loss is the #1 which uses biocompatible, nontoxic, blue light cause of death on the battlefield and #2 cause of death activated polymers to create a strong, thin, porous, in US civilian hospitals, including 25 % of all trauma quick drying and breathable casts for any body part. deaths. These numbers are expected to rise with With CaliCast the wearer may swim and bathe as the increased use of anticoagulants, especially those well as feel less encumbered due to the thin, low lacking an FDA-approved antidote. Cayuga Biotech is profile design which will allow enhanced mobility developing a commercially viable nanotherapeutic drug and ease of movement. There are currently casts on to stop bleeding. We deliver biomimetic polyphosphate the market that advertize as water compatible but (polyP) to wound sites to accelerate clotting, improving have shortfalls which the CaliCast design overcomes. upon current treatments that initiate clotting. Attaching The two competing products use a waterproof liner polyP to a nanoparticle significantly enhances shelf- under the traditional fiberglass and drain at each life to allow for prehospital use. This strategy employs end. CaliCast on the other hand does not need the biocompatibility and selective targeting to improve fiberglass layer and also breathes without requiring safety and efficacy. The therapeutic is easily applied to draining. The compact and breathable nature of bandages and sealants to treat injuries through topical CaliCast makes it particularly attractive for the application. We have completed the drug development pediatric, geriatric, military and veterinary markets stage and begun preclinical trials. where compactness and water compatibility are pains that CaliCast can relieve. Furthermore Calicast is cost competitive with the two other products in the waterproof cast space. CaliCast has a line of products planned to address the needs of the active orthopedic patient of any age or species!

8 UCLA Medical Device Partnering Conference Startup Company Profiles Startup Company Profiles

luid ynchrony

http://fluidsynchrony.com/ http://gi-logic.com/

Fluid Synchrony develops wirelessly controlled The mission of GI Logic is to continually innovate drug infusion systems for safe, accurate, and and evolve medical devices that help contribute localized administration of liquid drug formulations to human welfare and advance the field of directly to targeted tissue. This automated gastroenterology metronomic dosing maximizes therapeutic efficacy while minimizing unintended side effects. Our GI Logic was created to address an urgent need for patented microtechnologies enable a highly- convenient, low cost, sensor systems that can be desirable miniaturized form factor and superior deployed rapidly in the hospital, clinic and home power efficiency for implantable and wearable for diagnosis of digestive disorders. These sensor applications. Our high-performance micropump systems must provide network communication platform addresses multiple markets: laboratory capability for both local area mobile computing animal research, veterinary care, agriculture animal, devices as well as communication to remote assets. and human patient care. Fluid Synchrony has been Clinicians have traditionally relied on either the basic awarded over $1.6 million in SBIR funding over capabilities of a stethoscope or on invasive, often the past year to develop multiple product lines. complex, methods to diagnose and treat increasingly FluidSync™ microinfusion systems have been common GI disorders. Through innovation and successfully demonstrated in long-term research, GI Logic aims to develop a range of new in vivo studies and have been sold to customers in tools to help clinicians improve patient care and academia and the pharmaceutical industry. advance the field of GI medicine.

UCLA Medical Device Partnering Conference 9 Startup Company Profiles

Implantable microelectronic devices are used to treat QT Medical, Inc. is a spinoff of the Los Angeles conditions like arrhythmias, Parkinson’s disease, and Biomedical Research Institute (LA BioMed). back pain and other indications are under clinical Founded in 2013, QT Medical aims to lead the investigation. This industry’s market is expected to market for newborn screening of heart disease. grow at greater than 15% for several years, however Dr. Chang is Founder and CEO, Professor of these devices continue to use 50-year old designs Pediatrics at UCLA, who has 15 years research in consisting of platinum electrodes embedded in newborn cardiac screening. The first product— silicone insulation, connected to titanium-encased QT-ECG, the world’s smallest full function electronics. The size and efficiency of these devices 12-lead ECG system designed for use in newborns, cannot be improved using the material technologies will launch in 2015. QTScreen—an ECG system available today. Platinum Group Coatings (PGC) designed for newborn screening of long QT has developed a novel Electroplated Platinum syndrome, is currently in Phase II clinical trial. Iridium Coated (EPIC) electrode technology for This will be the first 12-lead ECG system that can biomedical stimulation/sensing. EPIC allows be used at home. 510(k) submission for QTScreen electrode size reduction by >100x without decrease is anticipated in 2016, and service for long QT in performance. EPIC enables chronic stimulation syndrome screening in newborns will launch soon using MEMS electrodes, currently not possible with after the FDA clearance. Cardioscreen—a wearable thin-film fabricated microelectrodes. Our process is device with pulse oximetry, phonocardiogram scalable, compatible with non-planar substrates and and 12-lead ECG for babies, is currently under patent-protected. PGC is currently selling electrodes development. QT Medical has received over $2.2 to research customers and engaging with medical million in funding from NIH. We are now seeking device manufacturers for collaborative development investors and strategic partners for product launch programs. and clinical trials.

10 UCLA Medical Device Partnering Conference Startup Company Profiles

UCLA Medical Device Technologies Available for Licensing

UCLA Medical Device Partnering Conference 11 solution’s mixing ratio and rate of delivery estimate precise placement. UCLA clini- Cardiovascular Devices based on past and present measure- cian Dr. Satoshi Tateshima in the Division ments of a patient’s blood-gas parameters, of Interventional Neuroradiology has Coil-Assisted Retrograde including pH. developed a novel catheter to help antici- pate the degree of foreshortening during UCLA Case No. 2013-076 Transvenous Obliteration stent deployment. The present technology LEAD INVENTOR: Thomas Mason (CARTO) Plug overcomes the inherent limitations of the Patent Status: Pending widely used braided and laser cut stents – Gastric varices (i.e. dilated submucosal providing a superior device with increased blood vessels) are a common complica- placement accuracy and ease of use. tion of portal hypertension in patients with Novel Application of Laser UCLA Case No. 2012-218 cirrhosis and other liver diseases and are Lithotripsy for Treating Vascular LEAD INVENTOR: Satoshi Tateshima associated with serious morbidity (e.g. Calcification bleeding) and increased risk of mortal- Patent Status: Pending - Pub. No. ity. An interventional technique called Traditionally, vascular bypass surgery has WO/2014/042900 balloon-occluded retrograde transvenous been considered the “gold standard” of obliteration (BRTO) has been shown to treatment for peripheral arterial disease. be effective in the management of gastric However, surgery is associated with signifi- Self-Navigating Intracardiac/ varices and is quickly gaining attention in cant morbidity and mortality, and 40% of Intravascular Catheter the United States. However, due to long these patients are not eligible for surgery. balloon indwelling time (4 - 48 hrs.), the Percutaneous Transluminal Angioplasty While fluoroscopy is frequently used to balloon used in BRTO may become a (PTA) has been introduced as an alterna- localize catheters within the body, its per- nidus for complications. UCLA researchers tive to surgical revascularization demon- formance is limited by the radiation expo- have introduced a new technique called strating favorable clinical outcomes, but sure, space, and noise and blurring effects coil-assisted retrograde transvenous oblit- still carries its own limitations. To overcome of the X-ray and acquisition system. Thus, eration (CARTO). In this approach, metallic limitations of PTA, UCLA researchers catheter-based procedures —particularly coils are utilized for occlusion of the shunt. have developed a special endovascular those that require high precision, such as They have also developed a new device catheter that can be used for laser-assisted accessing the coronary sinus—are limited that can automatically adjust its size and angioplasty under direct visualization. by fluoroscopy and technical operator diameter to the blood vessel and prevent This method also allows for irrigation and skills as are other imaging modalities. To dislodging of the deployed coils. Design extraction of ablation-induced debris, thus address the challenges of catheter place- features also include a central conduit that reducing the risk of distal embolization. ment, Dr. Peyman Benharash of UCLA’s enables the infusion of complementary This method is based on Holmium laser Division of Cardiothoracic Surgery and coagulative materials such as GelFoam®. and provides a higher energy and repeti- colleagues have designed a self-navigating catheter that contains sensors to deter- UCLA Case No. 2013-082 tion rate for smoother cutting and faster, mine its own position in the body. To date, LEAD INVENTOR: Edward Lee more efficient tissue ablation. the catheter design has been tailored to Patent Status: Pending UCLA Case No. 2012-565 accessing the coronary sinus, a common LEAD INVENTOR: Bashir Tafti site for interventional therapies. Sensors and other self-contained imaging modali- Improved Treatment of Patent Status: Pending - Pub. No. WO/2013/184697 ties will provide inputs to either an operator Metabolic Acidosis or an automated system that will drive the catheter to the appropriate location. Professors Thomas Mason and Jeffrey Novel Catheter for Precise UCLA Case No. 2012-108 Kraut in UCLA’s Department of Chemistry Stent Delivery and School of Medicine, respectively, have LEAD INVENTOR: Peyman Benharash developed improved materials and meth- Current therapeutic strategies for the Patent Status: Pending ods of treating acute metabolic acidosis, management of cerebrovascular disease a condition in which pH within a patient (CVD) include endovascular stents to has become abnormally acidic and can expand a narrowed or blocked artery. The be life-threatening. The inventors have flexible nature of the stent that permits developed more effective base-treatment expansion and enables passage through solutions involving a strong base, such as tortuous blood vessels also imposes a disodium carbonate, mixed with a weak technical challenge, known as foreshorten- base, such as sodium bicarbonate to raise ing, to the accurate placement of the stent. both intracellular and extracellular pH Foreshortening describes the change in while beneficially consuming dissolved car- length of the stent as it elongates to fit bon dioxide. Additionally, the investigators the confines of the delivery catheter and have conceived new methods of delivering shortens following its expansion within these formulations in a time- and spatially- the target vessel - leaving the surgeon to varying manner, thereby optimizing the

12 UCLA Medical Device Partnering Conference Unobstructing Microdevices Bioactive Endovascular Coils Method and Device for Treating for Self-Clearing Implantable Intracranial Vascular Aneurysms Catheters Researchers at UCLA have developed a detachable endovascular coil system with Inventors at UCLA have developed a device, Implanted medical catheters are now an increased biological activity. These coil and a method, for the therapeutic manage- integral part of clinical care. However, many materials are inherently bioactive and can ment of intracranial vascular aneurysms. chronically-implanted catheter systems be further coated with, or act as a delivery This technology involves the use of intra- are plagued with reduced performance vehicle for, bioactive or therapeutic agents, vascular catheters that can directly image as a result of accumulating biological such as drugs to control the inflammatory the aneurysm, and can occlude the entire debris. Dr. Jack Judy and colleagues in reaction inside an aneurysm. The innovation lumen of the aneurysm sac using liquid the Department of Bioengineering at UCLA maintains the mechanical flexibility of the sealing agents. The intracranial catheters have developed an unobstructing microde- coils, ensuring that they are highly effective are designed in various configurations so vice for self-clearing catheters that alleviates at preventing blood flow. These improve- that they can be used to treat aneurysms flow obstruction. The researchers designed ments will accelerate aneurysmal healing regardless of their neck size or location micro-mechanical mechanisms to disrupt and minimize their rate of recurrence. within the intracranial vascular system. the accumulation of biological material UCLA Case No. 2011-135 UCLA Case No. 1996-528 and keep catheter pores clear of debris. LEAD INVENTOR: Benjamin Wu LEAD INVENTOR: Tarik Massoud This device may be directly integrated into Patent Status: Pending - Pub. No. Patent Status: U.S. Patent Issued - commercially available catheter systems US 2014/0180395 A1 # 5,776,097 for use in existing surgical techniques (e.g. chronically implanted catheters). UCLA Case No. 2010-175 Brain Collateral Perfusion Neuro-Endovascular Ultrasound LEAD INVENTOR: Jack Judy Augmentation by Cerebral Thrombolysis Patent Status: Pending - Pub. No. Venous Pressure Modulation US 2011/0313340 A1 Researchers at UCLA have developed a UCLA researchers have developed a novel new method of treating stroke using ultra- method and device to improve cere- sonic energy. There are several advantages Dual Rotational Stent bral blood flow to about 50% of normal of this method over conventional fibrino- baseline value, thereby treating acute or lytic therapy: (1) ultrasound can recanalize Researchers at UCLA invented a novel chronic ischemia associated with stroke. arteries much quicker than fibrinolytic dual rotational stent device for the endo- The device and corresponding method therapy, (2) ultrasound does not cause vascular treatment of cerebral aneurysm uses applied pressure to artificially achieve bleeding complications, and (3) ultrasound without the need for placing coils in the collateral circulation in the brain. To can be more economical than fibrinolytic aneurysm lumen. The adjustable and increase cerebral venous pressure and therapy in itself and in overall hospital variable struts density pattern of the new thereby, redirect maldistributed blood flow, costs. stent device allows it to cover the orifice the device creates an occlusion of one or UCLA Case No. 1995-593 of the aneurysm. This is advantageous more veins coupled to the collapsed ves- LEAD INVENTOR: Cheng Ji for causing blockage of blood flow to the sel. The device consists of an elongated occluding aneurysm while sparing blood tubular member with proximal and distal Patent Status: U.S. Patent Issued - # 6,024,718 flow to perforators or side branches near ends for insertion into a patient’s superior the aneurysm neck. Specifically, the new vena cava (or other vein), an expandable compound stent has two main, but sepa- occluder located at the distal end of the rate components; one for being positioned tubular member (the occluder has an and stabilized in the parent vessel span- expanded and a collapsed state), a device ning the neck of aneurysm, and another to measure pressure at the distal end of for controlling the degree of blood flow into the tubular member, a device to measure the aneurysm. cerebral blood flow in the patient, and a controller programmed to actuate the UCLA Case No. 2009-668 expandable occluder as a function of the LEAD INVENTOR: Dieter Enzmann measured venous pressure and the mea- Patent Status: Pending - Pub. No. sured cerebral blood flow. WO/2014/028913 UCLA Case No. 2009-224 LEAD INVENTOR: David Liebeskind Patent Status: Pending - Pub. No. US 2010/0318114 A1

UCLA Medical Device Partnering Conference 13 Implantable Targeted Ultrasound Silicon Microsystems for High- CNS Technologies for Neuromodulation Throughput Analysis of Neural Circuit Activity Wireless Implantable System Electrical deep brain stimulation is the cur- to Restore Memory rent standard of care for many neurologi- Functional MRI (fMRI) and electroenceph- cal diseases, but the imprecise targeting alography (EEG) techniques can provide Traumatic brain injury (TBI) may cause of specific neural circuits by currently coarse-grained pictures of neuronal activity both anterograde and retrograde memory available trans-cranial stimulation devices in the brain; however, they are unable to impairment. While implantable deep brain limits its effectiveness. UCLA researchers provide information on rapidly changing stimulation (DBS) systems are FDA- have developed a prototype of an implant- activity of single neurons, which is key to approved for the treatment of Parkinson’s able ultrasound device for stimulation and unraveling how the brain codes informa- disease and epilepsy, there are currently modulation of neural circuits in the brain. tion. UCLA researchers in the Department no interventional therapies for memory This technology is the first millimeter-scale, of Neurobiology have developed a unique restoration in TBI patients. UCLA research- low frequency implantable ultrasound electrode array capable of simultane- ers have developed a wireless, implantable probe suitable for targeted invasive ultra- ously mapping neural activity from two DBS system that delivers electrical brain sonic stimulation. This device would offer or more brain structures. This technol- stimulation via specially designed elec- a novel form of neuromodulation, with dis- ogy addresses major technical obstacles trodes (UCLA Case No. 2014-287) in order tinct advantages over both electrical deep of recording single neuron activity and to restore and enhance the memory of brain stimulation and trans-cranial focused expands on the potential of neuronal moni- patients suffering from TBI. ultrasound technologies. toring by allowing single-cell-resolution measurements of activity from numerous UCLA Case No. 2014-959 UCLA Case No. 2014-512 networked brain structures. In addition to LEAD INVENTOR: Amit Mulgaonkar LEAD INVENTOR: Itzhak Fried enhanced recording performance, these Patent Status: Pending Patent Status: Pending new electrode array-probes will be more cost-effective to manufacture, as well as A Method for the Unsupervised Wireless Wearable Big Data smaller and hence less invasive. Detection of Biomarkers of Brain Machine Interface UCLA Case No. 2013-039 Epileptogenic Brain in Real Time LEAD INVENTOR: Sotiris Masmanidis In order to improve the investigation, Patent Status: Pending Dr. Weiss from the Department of diagnosis, and treatment of brain activity, Neurology has developed a method for the UCLA researchers have designed a user- real-time detection and quantification of friendly brain-machine interface (BMI) that Quantitative EEG Method to inter-ictal discharges and high-frequency consists of an implanted recording-and- Identify Individuals at Risk for brain oscillations (HFOs) associated with transmitting module, a wearable receiving- Adverse Antidepressant Effects epileptic seizures and neurological or and-forwarding module, and a mobile psychiatric disorders. The system or device post-processing unit. Where previous Antidepressant medication has demon- may process previously acquired EEG systems designed to monitor neural activity strated efficacy for the symptoms of depres- or MEG with a short turn-around time, are limited in data transfer rates and use sion, but some individuals may experience or receive input from a data acquisition physically connected wires, this newly adverse effects on mood during antidepres- device and operate in a fully automated, designed BMI can wirelessly transmit data sant treatment that could result in harm to real-time fashion. By distinguishing at an unprecedented rate of ~1 Giga-bit/ themselves or others. Researchers at UCLA between pathological discharges and nor- second. This BMI could support research have developed a method that identifies mal physiological brain activity, this device investigating brain activity mapping, the patients likely to experience adverse effects can automatically detect brain tumors and diagnosis of brain abnormalities, and the from antidepressant medication. A patient’s developmental abnormalities that generate development of new treatments to prevent response to the treatment is measured by seizures. or cure brain-related illnesses. using quantitative electroencephalographic UCLA Case No. 2014-699 UCLA Case No. 2014-495 recordings (QEEG). This method has been Lead Inventor: Shennan Weiss LEAD INVENTOR: Wentai Liu validated in a small double-blind placebo- controlled clinical trial with 97% accuracy. Patent Status: Pending Patent Status: Pending Patient response to medication was corrob- orated by using standard clinical checklists that diagnose adverse symptoms. UCLA Case No. 2006-262 LEAD INVENTOR: Aimee Hunter Patent Status: U.S. Patent Issued - # 8,521,270

14 UCLA Medical Device Partnering Conference Hydrogel Coatings on Medical Graphene Based Catalysts Device Materials Implants for Preventative and for Biomimetic Generation of Therapeutic Applications Antithrombotic Species Biodurable and Bioselective Coatings for Dental Implants In the case of open fractures, up to 50% Thrombogenicity (the tendency for blood of the patients suffer from osteomyelitis, a to adhere to a material’s surface) has The oral cavity is a complex ecosystem of bone infection caused by the introduction remained a major challenge for implanted microbial organisms, some being harmful of bacteria and other germs into the wound medical devices since their inception. and some beneficial. However, modern site. Researchers in the UCLA Department UCLA researchers from the Departments medicine has introduced materials and of Chemical and Biomolecular Engineering of Chemistry and Materials Science and implants that may disrupt the natural equi- have incorporated antibiotics into a novel Engineering have developed a graphene- librium and lead to oral health problems. amphiphilic polymer that was covalently based catalyst for generating HNO, an UCLA researchers are developing a series linked to titanium implants. The coating antithrombogenic species, for biomedical of materials that prevent the attachment allows for the local release of antibiotics applications. This material greatly extends and growth of harmful bacteria, but allow near the implant and has demonstrated the lifetime of antithrombogenicity by using selected neutral or beneficial flora to grow efficacy against S. aureus infections in endogenous and abundant glucose and at endogenous levels; much like the nor- vivo. By taking advantage of the polymer’s L-arginine for the production of HNO. The mal environment of healthy oral cavities. self-assembly nature, researchers were graphene-based conjugates can be incor- The benefits of this new paradigm for oral able to create a versatile structure with porated into polymer coatings that can be healthcare are realized by new materials control over the thickness of the hydrogel applied to biomedical devices. layers, the loading capacity of antibiotics that support bio-beneficial and selective UCLA Case No. 2014-521 environments for preventative care, rather and the polymer’s drug elution properties. LEAD INVENTOR: Xianfeng Duan than treating diseases after the fact. UCLA Case No. 2014-838 Patent Status: Pending UCLA Case No. 2015-463 LEAD INVENTOR: Tatiana Segura LEAD INVENTOR: Wenyuan Shi Patent Status: Pending Patent Status: Pending A Novel Polymer Platform for Drug Delivery Poly(p-xylylene) Polymer-Based Robust, Ultra-Flexible, Micro- Microfilms for Oral Delivery of Aggressive surgical resection and chemo- Encoded Ferromagnetic Tape for Therapeutics radiation therapy (CRT) are the dominant Bioseparation and Assembly treatment course for patients with Head Poly (p-xylylene), trade name Parylene, and Neck Squamous Cell Carcinoma Magnetic particles have found enormous is an FDA-approved material used as a (HNSCC), but these approaches often use in biomedical applications, including protective coating for medical devices, but negatively impact patient quality of life, drug delivery, cell separation, and as an its elution capabilities in pharmaceuticals including disfiguration and loss of facial MRI contrast agent. Dr. Dino Di Carlo and are less exploited. UCLA researchers have mobility in some cases. UCLA research- colleagues have developed a ferromagnetic utilized semi-porous poly (p-xylylene) film ers have developed a novel implantable tape, with user-defined microscale thick- as a stand-alone vehicle for the intraoral drug delivery device that reproducibly ness, size, and structure, on a flexible sub- delivery of pharmaceuticals with predeter- reduces tumor growth in vivo, bypassing strate with a user-defined elastic modulus. mined time scales and dimensions. The the traditional HNSCC treatment course. This technology can be attached alongside film is synthesized as a semi-porous patch The technology combines biocompatible microfluidic channels, Eppendorf tubes, to be placed in the mouth for long-term polymer sheets with anti-tumor drugs and catheters, and more to enable patternable (greater than 1 month) storage and deliv- immune-boosting proteins that can be and tunable separations of magnetic par- ery of therapeutic compounds. Due to the implanted to the surgical bed after debulk- ticles and significantly increase the speed benign synthesis process of the Parylene ing of the tumor. These layers of sheets are and control over particle positioning. film, a variety of therapeutic compounds highly customizable, as they can incorpo- rate multiple drugs at different concentra- UCLA Case No. 2015-154 can be incorporated, including small molecule drugs and proteins for anti-inflam- tions and release rates. LEAD INVENTOR: Dino Di Carlo matory, anti-cancer and anti-mucosal ulcer UCLA Case No. 2014-235 Patent Status: Pending therapies. LEAD INVENTOR: Benjamin Wu UCLA Case No. 2014-555 Patent Status: Pending LEAD INVENTOR: Dean Ho Patent Status: Pending

UCLA Medical Device Partnering Conference 15 Bidirectional Hyperelastic Improvement of Dental Resins: Covers for Woven Stents Decreased Toxicity and Improved Diagnostic Tools Biocompatibility Current stent designs frequently result ClearBot in hazardous wrinkling of the cover Resin-based and resin-containing materi- upon deployment, substantially increas- als are routinely used in dental practice To further our understanding of the human ing the risk of stent failure, and subse- as direct filling materials, fissure sealing body, it is essential to continuously develop quent morbidity. UCLA researchers have agents, and as bonding resins or resin new tools to visualize the 3D structure and developed a novel hyperelastic thin film cements for metal, porcelain, resin inlays, molecular details of complex organs and nitinol (HE-TFN) that can be used to cover veneers, crowns, and bridges. While the tissues, such as those of the brain and medical stents. This porous film maintains use of resin-containing materials is benefi- tumors. Current visualization techniques a deformation ratio that matches the com- cial to the appearance of patients, these include “clearing” the tissue sample by mercial stent distortion during deployment. materials carry the risks of cytotoxicity and infusing reagents into the tissue. However, As a result, potentially dangerous kinks allergy often through resins such as HEMA some methods involve lengthy experimen- and folds that arise from the crimping/ or TEGDMA. UCLA investigators have tal times or setups that may cause damage expanding process are substantially discovered that the presence of a chemi- to the tissue samples. UCLA researchers avoided. This ensures the conformal stent cal inhibitor (CI) can inhibit HEMA- and in the Department of Bioengineering have delivery and deployment. Furthermore, TEGDMA-mediated apoptosis (cell death) developed a device and an accompanying the design strategy and the hyperelastic in numerous human cell lines. Not only method of clearing multiple bulk tissue material allow customization of the cover was cell death inhibited, but the presence samples simultaneously that has been to different deformation ratios, making the of the CI also led to an increased viability proven to produce optically transparent novel cover widely applicable to various and function of treated cells. The results tissue samples from whole mouse organs. types of commercial stents. indicate that the CI prevents adverse Compared to conventional methods, the UCLA Case No. 2013-238 effects mediated by HEMA, TEGDMA and device also reduces the time, damage to bleaching agents and may be incorporated tissue samples, and quantity of reagents LEAD INVENTOR: Greg Carman into additive resin materials. that are necessary. Patent Status: Pending UCLA Case No. 2005-379 UCLA Case No. 2014-731 LEAD INVENTOR: Anahid Jewett LEAD INVENTOR: Dino Di Carlo Surface Modification of Patent Status: U.S. Patent Issued - Patent Status: Pending Endovascular Devices # 8,481,005

Current endovascular procedures for Arrayed Force Phenotyping of the treatment of vascular diseases use Single-Cells for High-Throughput a number of metallic devices including Screening and Analysis guidewires, stents and coils. Although these materials are commonly used, they Cell contractility is important to several have several limitations, such as friction physiological processes, such as cardiac generated during the installation proce- function and immune cell function, and dure and the need to be on blood thinning its dysregulation is implicated in a variety medication for a long time after implanta- of diseases. Current technologies used to tion. Researchers at UCLA have discov- assess cell contractility forces, however, ered a method of treating NiTi, “nitinol,” have limitations in objectivity of measure- sheets, wires, or stents that overcomes ments, throughput, and normalization of these limitations. The devices are treated test conditions. UCLA researchers from with a type of light, causing them to take the department of bioengineering have on super hydrophilic properties. This developed a simple and high-throughput conversion increases the affinity between tool for making well-defined quantitative the device and vascular tissue, resulting measurements of cell contractility that is in the acceleration of the healing process compatible with standard SBS well plate and a reduction in clotting. The hydrophilic formats. During the measurements, the device also demonstrates less friction dur- platform also maintains strict control over ing insertion and delivery. environmental conditions, cell orientation, UCLA Case No. 2008-007 spacing, and spreading. LEAD INVENTOR: Satoshi Tateshima UCLA Case No. 2014-709 Patent Status: U.S. Patent Issued - LEAD INVENTOR: Dino Di Carlo # 8,487,284 Patent Status: Pending

16 UCLA Medical Device Partnering Conference Single-Molecular Homogenous Multi-Modal Depth-Resolved A Rectal Mucosa Sampling Tool Amplified Detection in Confined Tissue Status Monitor Volumes Obtaining a sample of the rectal mucosa Researchers at UCLA have developed a is key to millions of diagnostic procedures Enzyme-linked immunosorbent assays portable tissue status monitor that sits on performed each year, including those for (ELISA) are widely used tools for ana- the surface of the skin and can provide colorectal and cervical cancer. Physician- lytical research in molecular biology depth-resolved information about tis- scientists at the UCLA David Geffen School research labs, and in clinical diagnostics. sue health status, which is of paramount of Medicine have developed an improved Researchers at UCLA have devised a importance where tissue is very thin or device for sampling the rectal mucosa. method to detect analytes using a modi- consists of multiple layers. The moni- The device design eliminates the need to fied sandwich ELISA that does not require tor uses a variety of sensors to perform completely insert the tube into the rectum. immobilization on a surface or a solid not only near-infrared spectroscopy, but This substantially reduces the discomfort phase. Using fractioned volumes, detec- also ultrasound, pressure, temperature associated with the procedure. In addition, tion signals can be measured as a binary and stretch sensing. In providing depth- other novel design implements make the cutoff signal, leading to higher sensitivity. resolved physiologic information, the tool more efficient, more precise, and safer Additionally, this assay does not require a technology may be used to monitor tissue for the patient. number of wash steps or sequential addi- after vascular surgery, during prolonged UCLA Case No. 2012-535 surgeries, or after mastectomy. In addition, tion of reagents. It only requires one mix LEAD INVENTOR: Jonathan Braun step and subsequent compartmentaliza- the device can fit easily under surgical Patent Status: Pending tion. This method can be used as a clinical dressings or casts, and operates wirelessly, diagnostic tool, including point of care making it rather simple to use. devices, and for analytical research. UCLA Case No. 2013-527 A Device for In Vivo UCLA Case No. 2014-180 LEAD INVENTOR: Warren Grundfest Characterization of Body Fluids LEAD INVENTOR: Dino Di Carlo Patent Status: Pending The rheological properties of certain fluid Patent Status: Pending reservoirs in the body, such as the vitre- Point-of-Care Detection of ous humor of the eye, hold clinical value Universal Bio Diagnostic, Drug Nucleic Acids for monitoring a variety of disorders as Delivery Device & Marker For well as evaluating effects of therapeutic treatments. However, no devices currently Correlated Optical & Electron DNA testing for infectious diseases at the point of care is beginning to enter clinical exist to rapidly assess fluid properties in Microscopy practice in both developed and develop- humans in vivo. Dr. Pirouz Kavehpour, ing countries. Dr. Bashir Tafti of UCLA’s Professor in the Department of Mechanical UCLA researchers from the Department of Department of Interventional Radiology has & Aerospace Engineering at UCLA, and Chemistry have developed nanodiamonds developed a method for rapid point-of-care colleagues have developed a needle-like with highly stable fluorescent centers that detection of nucleic acids. The approach probe to directly quantify the rheological are visible in both fluorescent imaging couples nucleic acid amplification with properties of human body fluid in real and electron microscopy. This technology an enzyme-based chemical reaction that time. Dr. Kavehpour’s work has demon- is non-toxic and non-blinking, and the supports subsequent quantification with strated that the physical properties of surface can be facilely conjugated with existing, portable devices. The detection human body fluid can be informative in biomacromolecules for targeting purposes. scheme precludes the use of fluorescence determining macromolecular structure and This technology enables the visualization or chemi- or bio-luminescence, thereby organization within an organ and that this of subcellular targeting of drugs and other improving the stability and accuracy of information may be useful for detecting biomacromolecules, and the measurement detection. The researchers have also and monitoring disease. This probe has and localization of subcellular heating. adapted the methodology for detecting the advantages of being minimally-invasive UCLA Case No. 2014-166 protein antigens without the need for lumi- and can measure fluid properties in vivo, LEAD INVENTOR: Louis Bouchard nescent or fluorescent tags. obviating the need for fluid extraction. Thus, this device can be used to diagnose Patent Status: Pending UCLA Case No. 2012-731 the risk or the presence of a degenerative LEAD INVENTOR: Bashir Tafti or pathologic state through measurement Patent Status: Pending of body fluid. UCLA Case No. 2011-208 LEAD INVENTOR: Pirouz Kavehpour Patent Status: Pending

UCLA Medical Device Partnering Conference 17 Microfluidic and Solid-State Beta and easy, requiring PDMS molding and Accurate and Rapid Micromixer Camera In Vitro Radioassay bonding only. With further development, it for Integrated Microfluidic could be used as a platform for a generation Devices There is a broad interest in targeting of high-throughput flow cytometers. kinases for drug discovery and patient UCLA Case No. 2011-038 UCLA researchers have designed and cre- diagnosis. UCLA researchers have devel- LEAD INVENTOR: Dino Di Carlo ated a novel mixer for microfluidic devices oped a polydimethylsiloxane microfluidic that combines the advantage of rapid mixing Patent Status: Pending - Pub. No. platform with a solid state beta camera US 2013/0233420 times of droplet-based mixers (typically to measure kinase activity on a limited found in continuous flow devices) with amount of patient samples. Miniaturizing precision and accuracy for controlling mixing the radiometric kinase assay brings Sheathless Inertial Cell Ordering volumes and ratios. The chip consists of several advantages over current radio- Microfluidic Device for Extreme three components: a digital droplet genera- metric assays. The amount of cell input Throughput Flow Cytometry tor, a droplet mixer, and a gas extractor. It required is reduced by 1,000 times over has been designed to easily integrate into conventional assays. This allows for direct Flow cytometry is regularly used for digital microfluidic chips, (i.e. chips that use experimentation on clinical samples that patient blood analysis. However, because valves to control fluid flow), as well as auto- are expensive or perishable. Also, the flow cytometry analyzes cells in a serial mated systems for a variety of applications. amount of radioactivity is reduced by at process, it is time-consuming and lacks The researchers have also built an interface least one order of magnitude, alleviating sufficient throughput (current methods between the mixing chip and a semi-auto- radiation safety concerns. Further, the top out at 10,000 cells/sec) to detect rare mated chemical synthesis unit to synthesize chips are inexpensive to custom design cells in blood which can have concentra- a radioactive labeling probe and immediately and produce. Finally, since most of the tions in the range of one in one quadril- label a biological molecule of interest. steps in the assay are under digital control, lion (1:1015). UCLA researchers have UCLA Case No. 2008-249 the performances of these assays are more developed a microfluidic chip capable of efficient, faster, and less labor-intensive. LEAD INVENTOR: Michael van Dam processing ~28 million cells per second. Patent Status: Pending – Pub. No. UCLA Case No. 2011-129 The design does not require a sheath US 2011/0103176 LEAD INVENTOR: Thomas Graeber stream, which simplifies the design without Patent Status: Pending - Pub. No. sacrificing efficiency. By coupling the chip US 2013/0244257 with high-speed imaging, the researchers Non-Invasive Optometric Medical can observe single cells to compare physi- Diagnostic Device cal characteristics of specifically targeted/ Microfluidic Platform to Control stained cells for accurate blood cell detec- UCLA researchers have created a fast, low- Particle Placement and Spacing tion and analysis. cost, and non-invasive approach for diag- in Channel Flow UCLA Case No. 2010-277 nosing various skin-related diseases. The LEAD INVENTOR: Dino Di Carlo technology takes advantage of the tempo- Researchers from the Department of ral response of endogenous fluorophores Patent Status: U.S. Patent Issued - Bioengineering at UCLA have developed a to a pulse of excitation light. A non-invasive # 8,693,762 microfluidic platform that controls particle- optometric device is used to measure skin wall and particle-particle interactions by autofluorescence which depends on the intertial flow. This permits fine manipulation health of the skin’s patient. The optometric of inter-particle spacing during solution device can be used to diagnose any dis- exchange. This microfluidic platform ease affecting the auto-fluorescence of the utilizes expansion and contraction channel skin. Examples include hyper-pigmentation geometries to make particle distribution diagnosis of non-melanoma skin cancer, more uniform in Reynolds number flow. photo-aging caused by UV, and monitoring Moreover, particle-particle spacing can be utriculus. It can also be used to determine tuned to a desired frequency. Unlike exist- the depth and size of a cancerous lesion ing particle manipulation methods, particle and changes in skin morphology. The manipulation by inertial flow gives extremely device could be used for—but is not lim- high-throughput without bulky external con- ited to—monitoring diabetes, skin-related trol units. The device fabrication is simple disorders, cancer, acne, and photo-aging. UCLA Case No. 2004-657 LEAD INVENTOR: Laurent Pilon Patent Status: U.S. Patent Issued - # 7,904,140

18 UCLA Medical Device Partnering Conference of the knee. Non-invasively applied to a Orthopedic Devices patient’s lower extremity, it provides an Radiation Therapy & objective measurement of the axial rotation Oncology Objective, Real-Time Acoustic of the tibia relative to the femur during the pivot shift exam. Measurement and Feedback A Breast Immobilization Device for Proper Fit and Fill of Hip UCLA Case No. 2012-519 to Improve Radiation Therapy Implants LEAD INVENTOR: Frank Petrigliano Dosimetry Patent Status: Pending - Pub No. Orthopaedic surgeons currently rely on WO/2013/123263 Breast setup and immobilization is a dif- manual assessment of the fit of implants ficult problem for external beam radiation in bone, leaving the procedure prone therapy of breast cancers. A lack of setup to technical errors that require revision An Improved Cast for Bone reproducibility with breast tissue results in surgeries. The present invention helps Fracture Healing sub-optimal dosimetry and tissue toxicity in improve implant fit by aiding surgeons’ non-targeted, healthy tissues. Dr. Ke Sheng, senses during the broaching procedure by The healing of a bone fracture often Associate Professor in UCLA’s Department analyzing and classifying acoustic features requires extended immobilization of the of Radiation Oncology, has developed a generated from hammering the broach into affected area. However, traditional plaster novel breast immobilization device that cancellous bone. The method monitors casts are heavy, uncomfortable, and com- allows for more comfortable support as well the impact between the femoral compo- monly cause skin irradiation and pressure as a robust radiation dosimetry improve- nent of a hip prosthesis with the patient’s point pain. Casts are also subject to mold- ment in breast tissue without the skin dose femur. The impact data is decomposed ing, degradation, and infection caused build-up effect that has plagued existing by a data acquisition and analysis device. by water and sweat. Researchers from methods. The device is low-cost and modifi- Metrics based on a number of acoustic UCLA’s Office of Intellectual Property and able for the desired breast morphology. features are calculated to determine the from the Department of Bioengineering UCLA Case No. 2013-077 fit and stability of the broach in the femur. have developed an improved layered cast Results are classified and output to a user using lighter, synthetic materials that allow LEAD INVENTOR: Ke Sheng interface to assist the surgeon. greater water permeability than exist- Patent Status: Pending - Pub. No. ing casts. The new cast also allows for WO/2014/074602 UCLA Case No. 2014-935 reversible hardening of the cast to allow LEAD INVENTOR: George Hafzalla for adjustments and removal of pressure Patent Status: Pending points over the course of application. This Magnetic Resonance Imaging new cast advances bone fracture treat- (MRI) Device for Improved High- ment by improving the hygiene associ- Dose-Rate (HDR) Brachytherapy A Novel Device for Quantifying ated with cast-wearing and by increasing Treatment Planning Rotational Stability of the Knee patient comfort through its adjustability and enhanced mobility. Internal radiation therapy (brachytherapy) The current standard for determining UCLA Case No. 2012-755 involves the positioning of tiny, radiation- anterior cruciate ligament (ACL) recon- emitting sources within tumor tissue by using LEAD INVENTOR: Benjamin Wu struction effectiveness, the Lachman test, delivery devices such as catheters, needles only measures translational stability. For Patent Status: Pending or other hollow conduits. Dr. Daniel Ennis, rotational stability, the pivot shift test is Dr. Jeffrey Demanes, and colleagues in widely accepted, though it lacks an objec- UCLA’s Department of Radiological Sciences tive means of quantification and current have developed a device that allows for the devices are large, fixed-position constructs effective imaging of the radiation-delivering that are impractical for clinical use. Dr. catheter and the surrounding tissue. Under Petrigliano and colleagues in UCLA’s MRI, the device can be detected with high Department of Orthopaedic Surgery have contrast, thereby providing valuable position- developed a novel microelectromechanical ing information of the treatment catheters system (MEMS) gyroscope with specific relative to the tumor and normal tissue. The software architecture to quantitatively device will allow optimal positioning of the assess both rotational and linear stability radiation source for the purpose of radiation therapy. This device has utility in visual- izing catheter placement in the body where brachytherapy is the preferred treatment strategy and where catheters are used as brachytherapy conduits. UCLA Case No. 2012-546 LEAD INVENTOR: Daniel Ennis Patent Status: Pending

UCLA Medical Device Partnering Conference 19 treatment of these abnormalities. UCLA measurements suggestive of complications Sensors & Patient researchers have developed a system that before or after surgery enabling earlier Monitoring Devices records and analyzes electrical signals discharge from the hospital and safer from heart neurons. This technology outpatient monitoring. enables the detection of functional abnor- UCLA Case No. 2014-499 Autonomous Thermoelectric malities associated with heart disease, LEAD INVENTOR: Dieter Enzmann Energy-Harvesting Platform for and can improve diagnosis, continuous Biomedical Sensors monitoring, and treatment. Patent Status: Pending UCLA Case No. 2015-093 To make thermoelectric energy harvesters (TEH) a truly autonomous energy source LEAD INVENTOR: Kalyanam Shivkumar Prediction of Clinical for size-constrained, wireless biomedical Patent Status: Pending Deterioration sensors and eliminate the need for bat- teries, it has been necessary to drastically Dr. Scott Hu at UCLA has developed a improve their energy density and conver- ECG-gated Pulsed Wave Doppler method to predict clinical deterioration of sion efficiency. UCLA researchers from the Ultrasound Device for Zebrafish patients, which could warn clinicians of Department of Electrical Engineering have impending clinical deterioration before its developed an autonomous energy source A real-time non-invasive methodology occurrence. This predictive method is able for implantable biosensors by develop- to monitor the structure and function of to detect rare events of patient deteriora- ing a TEH that can operate with a 68% cardiac organs in small animals is needed tion with high sensitivity and improve end-to-end peak efficiency with <20ms in research and technology development. results as more samples are entered. This tracking time, and start-up voltages as UCLA researchers have developed a high method had a positive predictive value that low as 65mV. A 645µW regulated output frequency ultrasound transducer that can was 50% greater than traditional statisti- power was harvested from the head of simultaneously acquire an electrocardio- cal models. It is currently being used to a rat implanted with the new TEH while gram and an echocardiogram to moni- predict sepsis in leukemia patients, but is achieving a 7.9x improvement in regulated tor the physiological conditions of small being adopted to predict respiratory failure, power density. animals in real-time and in a non-invasive myocardial infarction and other common manner. The device and methodology can critical care aliments. UCLA Case No. 2015-245 be used in monitoring the health of cardiac UCLA Case No. 2014-445 LEAD INVENTOR: Dejan Markovic tissue during post cardiac transplantation LEAD INVENTOR: Scott Hu Patent Status: Pending and drug screening. Patent Status: Pending UCLA Case No. 2015-087 Non-Invasive System for LEAD INVENTOR: Tzung Hsiai Classification of Individual’s Patent Status: Pending Saturation-Tolerant Intake Electrophysiological Recording Interface UCLA researchers have developed a Wireless Remote Sensing method for processing data from piezo- of Changes in Fluid Filled Weak electrophysiological input signals electric sensors worn around the neck in Containers (EEG, ECG, EMG) are often detected by order to more accurately assess what foods digitizing them using a large voltage gain in an individual has ingested. Algorithms are Trials of remote sensing of patient met- order to achieve a low background noise being refined that employ a spectrogram rics, such as blood pressure, have been level. However, in noisy environments, the analysis towards multiple piezoelectric sen- successful in reducing hospital visits and loud signals from motion artifacts, unrelated sor data. This method could greatly improve medical costs by increasing the accuracy biological signals, or man-made interfer- monitoring of food intake in an effort to bet- and amount of data, while lowering the ers saturate the input signal and prevent ter meet weight management goals. amount of staff time necessary to take the their detection. Researchers at UCLA have data. However, for accurate fluid manage- designed an electrophysiological signal pro- UCLA Case No. 2015-108 ment, staff must measure and analyze the cessing device that can measure EEG, ECG, LEAD INVENTOR: Majid Sarrafzadeh fluids, their flow rates, and their composi- and EMG signals with high sensitivity in noisy Patent Status: Pending tions in order to ensure quality care. UCLA environments that would otherwise drown researchers have developed a novel device out weak signals. An on-chip system has and method for continuous and dynamic been developed that shows a 20x improve- A Novel Method and Apparatus monitoring of patient fluids. This technol- ment for saturation tolerance over existing to Monitor Cardiac Disease ogy may extend beyond patient fluids to systems of similar power, noise, and area. other medium such as evaluation of air UCLA Case No. 2014-404 Most heart conditions are characterized (air leaks) following lung surgery or injury LEAD INVENTOR: Dejan Markovic by detectable abnormalities of electrical that guide timely management of drainage (neural) heart function, but there currently tubes. Wireless remote sensing technology Patent Status: Pending exists very limited technology for the pro- may quickly detect changes in fluid or air longed active monitoring and early stage

20 UCLA Medical Device Partnering Conference BigFoot: Analysis, Monitoring, Networked Sensor Systems for Corneal Hydration Sensing with Tracking, and Sharing of Remote Patient Monitoring THz Illumination Biomedical Features of Human Appendages Current methods to monitor sleep require Proper corneal hydration levels are critical patients to go to Sleep Monitor Centers to maintaining optical vision. Researchers Many diabetic patients suffer from periph- with large electrophysiology, respiratory at UCLA have developed an imaging sys- eral neuropathy, a disorder that results in measurement, and motion measurement tem to detect corneal hydration levels by the loss of sensation in their extremities. systems. UCLA researchers have devel- illuminating the cornea with low power, low Individuals with this condition may develop oped an innovative Wearable-to-Enterprise energy, terahertz (THz) frequency light and severe infections from sores on the soles Sleep Monitoring System to serve the mar- measuring the magnitude of the reflected of their feet without their knowledge, which ket demand for Out of Center Sleep Testing THz signal. The system is capable of can lead to the loss of limbs. BigFoot uses (OCST) in adult patients. This technology resolving 0.18% changes in the water customized software integrated with a combines monitoring, data archiving, concentration of the cornea in vivo and commercial flatbed scanner that enables reporting, usage assurance, and sub- results suggest a ~3x increase in dynamic easy image acquisition and analysis of feet ject guidance. The system is comprised range over ultrasound-based pachymetry. abnormalities. For patients that find check- of wearable head, chest, and leg units. This system can be used for detecting ing their feet difficult, this tool can easily These units contain sensors for airflow, inflammation, immune responses, edema, monitor, track data and share image data electroencephalography (EEG), electro- or other disease in the cornea. oculography (EOG), electrocardiography in order to identify abnormalities early and UCLA Case No. 2012-100 (ECG), respiratory effort and rate, electro- prevent complications. LEAD INVENTOR: Martin Culjat myogram (EMG), sleep time, motion, blood UCLA Case No. 2014-132 oxygen, auditory sensing, and actigraphy Patent Status: U.S. Patent Issued - # 8,690,331 LEAD INVENTOR: Aydogan Ozcan sensing measurements. Copyright Status: Pending UCLA Case No. 2013-008 LEAD INVENTOR: William J. Kaiser Exercise-based Entertainment Method to Non-Invasively Patent Status: Pending - Pub. No. Controller WO/2014/066059 Determine Respiration Rate To help combat childhood obesity, UCLA Using Pressure Sensors researchers in the Department of Electrical NMR Probe for Detection of Engineering have developed an exercise- UCLA researchers in the Department of Microstructures based entertainment controller system. Electrical Engineering have developed The system allows children to use enter- a noninvasive method for measuring Nuclear Magnetic Resonance (NMR) tainment appliances, such as the televi- respiratory rate. Although not required, spectroscopy is a widely-utilized method sion or computer, based on the amount of the system is intended to be used when for analyzing small molecule compositions. physical activity they have done throughout the patient is sleeping, either at home or However, NMR sensitivity is too poor for the day, recorded via a pedometer. When in a clinical setting. While the user is lying diagnostic purposes and has limited its a child plugs the pedometer into their on top of the mattress embedded with use to academic research. A key compo- PC, the software retrieves data from the pressure sensors, the system calculates nent responsible for the sensitivity is the pedometer, and allots a time budget for and displays the breathing rate of the user, NMR probe, which holds the sample as it the child to use entertainment appliances. which can be used to identify irregular is inserted into the magnetic field. UCLA When the time budget is exhausted, the breathing patterns. Of particular note is researchers developed a NMR probe with power control module shuts off the cor- that the system can detect episodes of sensitivity superior to current designs. It responding appliance via an RF signal. apnea and subsequently alert a medical contains a novel noise reduction mecha- UCLA Case No. 2009-496 professional or caregiver. The graphi- nism, making it the most sensitive probe LEAD INVENTOR: Majid Sarrafzadeh cal user interface developed as part of of its kind. These properties allow the the invention provides several additional detection of metabolites at the single cell Patent Status: Pending - Pub. No. US 2013/0090213 features. level. Additionally, the probe has a planar UCLA Case No. 2013-009 configuration, making it ideally suited for LEAD INVENTOR: Majid Sarrafzadeh microfluidic chips used for diagnosis and prognosis. It is also made with an ultra Patent Status: Pending small detection region, 0.08 mm length by 0.05 mm width by 0.05 mm high, for samples of small volume and low concentration (such as biological samples). UCLA Case No. 2012-550 LEAD INVENTOR: Louis Bouchard Patent Status: Pending - Pub. No. WO/2014/011937

UCLA Medical Device Partnering Conference 21 Covalt Uterine Removal System Organ Resuscitation Solution Surgical Tools & System for Enhanced Liver When a hysterectomy is performed due Transplantation Inferior Vena Cava Filter to the presence of cervical cancer, the risk of causing cancer cells to be pushed Retrieval Device Researchers in the Department of Surgery into neighboring tissue and possibly grow and UCLA Pfleger Liver Institute have into new malignant tumors is great. While An inferior vena cava (IVC) filter is a medi- developed a novel solution and system specimen retrieval bags have been used cal device that is placed into the IVC to to minimize the tremendous degree of in conjunction with uterine manipulators prevent life-threatening conditions such ischemia and reperfusion injury (IRI) to avoid the spillage of cancer cells, some as pulmonary emboli. Removing the filter associated with liver transplantation. The studies have reported that spillage still by pulling it back through the jugular invention serves to replenish exhausted occurs over 10% of the time. Dr. Cohen vein requires easy access to the retrieval nutrients and resuscitate the organ before has designed a specimen retrieval bag hook. There is a significant risk associ- revascularization. In a swine model, use that utilizes air compression technology ated with the removal of an IVC filter. If the of the novel solution and system dem- and attaches to the uterine manipulator retrieval hook is in an inaccessible location onstrated enhanced liver function and in order to further reduce the spillage of in the body, then the risk is significantly improved survival compared to con- cancer cells during hysterectomies and elevated. Physicians at UCLA Department ventional approaches. This system may other tumor removal processes. of Radiology have invented a new IVC filter salvage livers, deemed to have incurred retrieval system which can be used for UCLA Case No. 2014-395 severe degree of ischemic injury and extracting IVC filters when the hook is not LEAD INVENTOR: Joshua Cohen discarded, to transplantable organs. A solution and system to alleviate organ accessible for capture with a snare (e.g. Patent Status: Pending embedded in the vessel wall). damage from IRI would have significant consequences on patient outcomes as well UCLA Case No. 2014-960 Image-Guided Irrigating as the availability of transplantable organs. LEAD INVENTOR: Stephen Kee Suction Cannula for Removal of UCLA Case No. 2012-292 Patent Status: Pending Intracerebral Hemorrhage and LEAD INVENTOR: Johnny Hong Other Lesions Patent Status: Pending - Pub. No. Percutaneous Catheter for Lung US 2014/0329221 Intracerebral hemorrhages (ICHs) are Assist Device potentially life-threatening conditions that occur when a blood vessel ruptures within A Video-Guided Chest Tube Some patients with severe lung disease the brain and causes an accumulation need to be treated with ECMO systems Insertion System of blood. Dr. Neil Martin at UCLA has that oxygenate the blood using extra- designed a simple multifunctional cannula Dr. Robert Cameron, Professor of Clinical corporeal, bedside machines. Currently system for performing minimally invasive Cardiothoracic Surgery and Surgical used catheters for ECMO systems suffer image-guided evacuation of ICHs. After Oncology in the Department of Surgery at from two primary disadvantages: blood making a small burr hole in the skull, the UCLA, has designed a novel trocar system that has already been oxygenated often cannula system is inserted toward areas that supports real-time visual monitoring of gets re-circulated through the system; of localized bleeding to both evacuate chest tube placement. Thousands of chest and the catheter’s strong dependence on excess blood and irrigate the wound site tubes are placed annually into the pleural position results in inefficiencies when a until hemostasis is reestablished. With space of patients who have excessive air patient inevitably moves. Dr. Ardehali has multiple instrument adapters, this system and/or fluid collapsing the lung. Currently, designed a catheter that overcomes these is capable of performing visual endoscope chest tube placement involves either a inefficiencies in ECMO catheter design guidance, stereotactic image guidance, extremely painful “medieval” incision and by having both more stability during use MRI image guidance, and computerized clamp technique or a trocar/dilator system, and a better fluid flow design that reduces tomography image guidance. Additionally, both of which are “blind” procedures often re-circulation. Dr. Martin’s instrument may be adapted to leading to poor tube position, organ dam- UCLA Case No. 2014-642 allow the use of a rotational clot or tissue age, and even death. Dr. Cameron’s device LEAD INVENTOR: Abbas Ardehali fragmentation device for hematomas with capitalizes on existing medical video Patent Status: Pending higher levels of blood clotting. technology to provide real-time monitoring and guidance of anatomical position of the UCLA Case No. 2014-320 chest tube during placement. Lead Inventor: Neil Martin UCLA Case No. 2012-287 Patent Status: Pending LEAD INVENTOR: Robert Cameron Patent Status: Pending

22 UCLA Medical Device Partnering Conference Lung Isolation System Laser-based Bacterial Disruption Expandable Mechanical for Treatment of Infected Wounds Distension Device for Hollow Researchers at UCLA have invented a Organ Growth novel system that achieves reliable lung Wound infections are difficult to treat isolation using a standard large bore single because bacteria form biofilms that Short gut syndrome is a condition in lumen endotracheal tube, which maxi- encase the bacteria. This barrier formed which patients have insufficient length mizes compatibility with other devices. by the bacteria prevents white blood cells of intestine to maintain normal digestion The system enables true dual lumen lung and antibiotics from entering and killing and absorption. In the United States, over isolation/ventilation thus enabling all the the bacteria. Researchers at UCLA have 100,000 patients suffer from the disease benefits of both a double lumen tube and developed a novel technology using laser each year. Researchers at UCLA have a bronchial blocker (the current methods generated shockwaves to disrupt bacte- developed a device to mechanically stretch of treatment) without the downsides of rial biofilms. Laser is applied to tissue out the intestine through the applica- either. It also incorporates a video visual- coated with a thin metallic film. The metal tion of longitudinal force. The device is ization system, thus precluding the need absorbs the laser, exfoliates, and launches made of shape memory materials such as for traditional fiberoptic bronchoscopy. a mechanical stress wave (shockwave) nickel-titanium or biocompatible polymers. UCLA Case No. 2011-739 through the tissue that disrupts the During implantation, the device is col- bacterial biofilms. A second wave is LEAD INVENTOR: Nir Hoftman lapsed to its minimum size, followed by then generated through a gel containing deployment into the intestinal tract via a Patent Status: Pending - Pub. No. nano-encapsulated antibiotics and silver WO/2013/188845 push rod. The structure then binds to a nanoparticles, and the antibiotic and silver particular location, and slowly expands nanoparticles are propelled into the tissue. over a period of several weeks. In doing so, Robotic Micro-Surgery System Thus, this technology not only disrupts the it applies longitudinal force, resulting in the bacterial biofilms but also delivers antibiot- lengthening of the intestine. Researchers at UCLA have developed a ics into the tissue. robotic system that performs complete UCLA Case No. 2009-227 UCLA Case No. 2009-230 micro-surgical procedures by exactly mim- LEAD INVENTOR: Greg Carman icking the motion of a joystick controlled LEAD INVENTOR: Warren Grundfest Patent Status: Pending - Pub. No. by a surgeon. The system incorporates Patent Status: Pending WO/2010/124126 multiple arms, which can be moved separately or in unison. Each arm holds a surgical instrument that is moved in real time, has high range of motion, and has access to a universal cartridge that facili- tates connections for multiple utilities. The instrument precision is further refined by filtering and removing the natural tremor of the surgeon’s hand. Additionally, because micro-surgery requires the instrument to mechanically maintain a fixed-point of rotation at the site of penetration, the system incorporates an integrated tracking system that allows the robot to compensate for patient movement. The tracking system also triggers automatic termination in the event that the patient moves beyond a determined threshold. UCLA Case No. 2009-300 LEAD INVENTOR: Tsu-Chin Tsao Patent Status: Pending - Pub. No. WO/2011/088400

UCLA Medical Device Partnering Conference 23 Notes:

______

______The UCLA Office of Intellectual Property and Industry Sponsored Research would like to acknowledge our Industry Advisors for their guidance and support.

SPONSORS:

INDUSTRY PARTNERS:

MEDICAL

IN COORDINATION WITH:

O ceUCSB of Technology & Industry Alliances

HOSTED BY: Connect

UCLA TechMatch Service

http://oip.ucla.edu/industry/techmatch

One of the best ways to keep up to date on emerging technologies from UCLA is via our TechMatch Service. Based on the technology interest areas you specify when you sign up, our office will then provide ongoing updates to you as new technologies arise that appear to match your interest areas.

Twitter @UCLAinventsO ce of Intellectual Property and Industry UCLA Monthly SponsoredNewsletter Research www.UCLAinvents.com

O ce of Intellectual Property and Industry Sponsored Research

For Technology Licensing or Research Collaboration Inquiries please contact us: [email protected] 310-794-0558